These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19025967)

  • 1. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.
    Ploeger BA; Holford NH
    Pharm Stat; 2009; 8(3):225-38. PubMed ID: 19025967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining and labeling disease-modifying treatments for Alzheimer's disease.
    Cummings JL
    Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial treatment length optimization with an emphasis on disease progression studies.
    Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2009 Mar; 49(3):323-35. PubMed ID: 19246730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease modifying trials in Alzheimer disease: methodological and statistical issues.
    Andrieu S; Rascol O; Lang T; Grandjean H; Vellas B
    J Nutr Health Aging; 2006; 10(2):116-7. PubMed ID: 16554944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
    Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
    Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining disease-modifying therapies for PD--a road map for moving forward.
    Olanow CW; Kieburtz K
    Mov Disord; 2010 Sep; 25(12):1774-9. PubMed ID: 20839307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
    de Carvalho M; Swash M
    Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Milestones in movement disorders clinical trials: advances and landmark studies.
    Olanow CW; Wunderle KB; Kieburtz K
    Mov Disord; 2011 May; 26(6):1003-14. PubMed ID: 21626545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling and design of cross-over trials.
    Jones B; Donev AN
    Stat Med; 1996 Jul; 15(13):1435-46. PubMed ID: 8841653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project.
    Barnhart HX; Caldwell MB; Thomas P; Mascola L; Ortiz I; Hsu HW; Schulte J; Parrott R; Maldonado Y; Byers R
    Pediatrics; 1996 May; 97(5):710-6. PubMed ID: 8628612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis: disease-modifying antirheumatic drugs.
    Kirwan JR; Currey HL
    Clin Rheum Dis; 1983 Dec; 9(3):581-99. PubMed ID: 6360514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of clinical trials of gene therapy in Parkinson disease.
    Lewis TB; Standaert DG
    Exp Neurol; 2008 Jan; 209(1):41-7. PubMed ID: 17920590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
    Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ;
    Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.